特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

前立腺がん診断の世界市場:市場規模・シェア・動向分析、部門別予測 (検査の種類別 (予備検査、確認検査 (PCA3、経直腸超音波、生検))・地域別)

Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Preliminary, Confirmatory (PCA3, Trans-rectal Ultrasound, Biopsy)), By Region, And Segment Forecasts, 2020 - 2027

発行 Grand View Research, Inc. 商品コード 726439
出版日 ページ情報 英文 145 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
前立腺がん診断の世界市場:市場規模・シェア・動向分析、部門別予測 (検査の種類別 (予備検査、確認検査 (PCA3、経直腸超音波、生検))・地域別) Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Preliminary, Confirmatory (PCA3, Trans-rectal Ultrasound, Biopsy)), By Region, And Segment Forecasts, 2020 - 2027
出版日: 2020年02月19日 ページ情報: 英文 145 Pages
概要

当レポートでは、世界の前立腺がん診断の市場について分析し、市場の基本構造や主な促進・抑制要因、検査の種類別・地域別の市場動向見通し (今後6年間分)、主要企業のプロファイルと戦略展開状況、といった情報を取りまとめてお届けいたします。

第1章 調査方法・範囲

第2章 エグゼクティブサマリー

第3章 前立腺がん診断市場:変動要因・傾向・範囲

  • 市場関連構造の分析
    • 母体市場/派生市場
  • 製品普及率・成長率の見通し:マッピング
  • 規制の枠組み
    • 医療費償還のフレームワーク
    • 基準とコンプライアンス
  • 市場のダイナミクス
    • 市場促進要因の分析
    • 市場抑制要因の分析
    • 市場機会の分析
    • 市場の課題の分析
  • 前立腺がん診断市場:分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • 主な資本取引・事業提携の分析

第4章 前立腺がん診断市場:企業別分析

  • 昨今の市場動向とその影響度の分析:主要企業の場合
  • 企業の分類
  • 公開企業
  • 非公開企業

第5章 前立腺がん診断市場:実績値・予測値の分析、検査の種類別

  • 市場の定義と範囲
  • 市場シェア分析:検査の種類別
  • 部門別のダッシュボード
  • 世界の前立腺がん診断市場:検査の種類別
  • 市場規模・予測と動向分析
  • 予備検査
    • 市場規模の動向見通し (金額ベース、通算12年間分)
  • 確認検査
    • 市場規模の動向見通し (金額ベース、通算12年間分)
    • PCA3検査
    • 経直腸的超音波検査
    • 生検

第6章 前立腺がん診断市場:実績値・予測値の分析、地域別

  • 市場動向 (概略):地域別
  • 市場シェア分析:国別
  • SWOT分析:要素別・地域別 (政治的/法的/経済的/技術的要因)
  • 市場規模とその予測、動向分析 (通算12年間分)
    • 北米
    • 欧州
    • ラテンアメリカ
    • アジア太平洋地域
    • 中東・アフリカ

第7章 企業プロファイル

  • 企業プロファイル
    • MDxHealth
      • 企業概要
      • 財務実績
      • 製品の相互比較
      • 戦略展開状況
    • 3D Signatures
    • Genomic Health
    • Abbott
    • OPKO Health, Inc.
    • Siemens Healthcare GmbH
    • DiaSorin S.p.A.
    • bioMerieux SA
    • F. Hoffman La Roche Ltd.
    • Beckman Coulter, Inc.
    • Myriad Genetic, Inc.
図表

List of Tables

  • Table 1 List of key distributors and channel partners
  • Table 2 List of key emerging companies'/product disruptors/innovators
  • Table 3 North America Prostate Cancer Diagnostics Market, by countries, 2016 - 2027 (USD Million)
  • Table 4 North America Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 5 U.S. Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 6 Canada Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 7 Europe Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 8 U.K. Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 9 Germany Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 10 France Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 11 Italy Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 12 Spain Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 13 Russia Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 14 Asia Pacific Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 15 Japan Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 16 China Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 17 India Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 18 South Korea Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 19 Australia Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 20 Singapore Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 21 Latin America Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 22 Brazil Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 23 Mexico Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 24 Argentina Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 25 MEA Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 26 South Africa Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 27 Saudi Arabia Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)
  • Table 28 UAE Prostate Cancer Diagnostics Market, by test type, 2016 - 2027 (USD Million)

List of Figures

  • Fig. 1 Prostate Cancer Diagnostics Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 Prostate Cancer Diagnostics Market Snapshot (2019)
  • Fig. 8 Prostate Cancer Diagnostics Market: Segment Snapshot (2019)
  • Fig. 9 Competitive Insights (2019)
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Prostate Cancer Diagnostics Market Driver Impact
  • Fig. 15 Prostate Cancer Diagnostics Market Restraint Impact
  • Fig. 16 Prostate Cancer Diagnostics Market Opportunities Impact
  • Fig. 17 Prostate Cancer Diagnostics Market Challenges Impact
  • Fig. 18 Porter's Five Forces Analysis
  • Fig. 19 SWOT Analysis, By Factor (Political & legal Economic and technological)
  • Fig. 20 Strategic alliance analysis
  • Fig. 21 Recent developments & impact analysis, by key market participants
  • Fig. 22 Key company market share analysis, 2019
  • Fig. 23 Company market share/ranking, by region
  • Fig. 24 Company market position analysis
  • Fig. 25 Product market share analysis, 2019 & 2027
  • Fig. 26 Segment dashboard
  • Fig. 27 Global Prostate Cancer Diagnostics Market, by Test Type, 2016 - 2027 (USD Million)
  • Fig. 28 Global Confirmatory Tests Market, 2016 - 2027 (USD Million)
  • Fig. 29 Global PCA3Test Market, 2016 - 2027 (USD Million)
  • Fig. 30 Global Trans-rectal Ultrasound Market, 2016 - 2027 (USD Million)
  • Fig. 31 Global Biopsy Market, 2016 - 2027 (USD Million)
  • Fig. 32 Prostate Cancer Diagnostics Market Snapshot
  • Fig. 33 North America Prostate Cancer Diagnostics Market Share Analysis by country, 2019
  • Fig. 34 Europe Prostate Cancer Diagnostics Market Share Analysis by country, 2019
  • Fig. 35 Asia Pacific Prostate Cancer Diagnostics Market Share Analysis by country, 2019
  • Fig. 36 Latin America Prostate Cancer Diagnostics Market Share Analysis by country, 2019
  • Fig. 37 Middle East and Africa Prostate Cancer Diagnostics Market Share Analysis by country, 2019
  • Fig. 38 North America SWOT Analysis, by factor (political & legal, economic and technological)
  • Fig. 39 Europe SWOT Analysis, by factor (political & legal, economic and technological)
  • Fig. 40 Asia Pacific SWOT Analysis, by factor (political & legal, economic and technological)
  • Fig. 41 Latin America SWOT Analysis, by factor (political & legal, economic and technological)
  • Fig. 42 Middle East and Africa SWOT Analysis, by factor (political & legal, economic and technological)
目次
Product Code: GVR-2-68038-548-9

The global prostate cancer diagnostics market size is expected to reach USD 7.65 billion by 2027, registering a CAGR of 13.2% during the forecast period, according to a new report by Grand View Research, Inc. Major drivers include increasing government initiatives, high prevalence of prostate cancer, and technological advancements in confirmatory diagnostic tests.

High prevalence of the disease across the world is anticipated to be one of the major factors propelling the growth. According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer during the lifetime. It also states that the disease is the second most common form of cancer in U.S. after skin melanoma with over 174,650 new cases diagnosed in 2019.

Rise in government initiatives to enhance research associated with effective diagnosis and treatment is expected to boost growth of the market during the forecast period. For instance, the National Cancer Institute (NCI) initiated the study Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress (RESPOND). It is the largest collaboration to study the non-biological and biological factors associated with the disease among African American men. The initiative was launched by the NCI, National Institute on Minority Health, and Health Disparities in collaboration with Prostate Cancer Foundation; with a funding of USD 26 million.

Researchers from the University of Norfolk and East Anglia have developed a non-invasive urine test-the PUR test-for the diagnosis of aggressive prostate cancer. This test is performed on samples collected at home thereby preventing uncomfortable rectal examination. Additionally, researchers at Karolinska and KTH Institute concluded that the use of Artificial Intelligence (AI) in spatial transcriptomics can aid in the early detection, thereby, improving clinical diagnosis and treatment. Thus, such advancements are anticipated to positively impact the market growth in near future.

Approval of new diagnostic tests are expected to further boost market growth. For instance, in 2019, Bio Techne announced the approval from the New York State Department of Health for a liquid biopsy based test named ExoDx Prostate IntelliScore. The test assists clinicians to determine the need for biopsy with ambiguous PSA test result. Thus, rising disease prevalence coupled with technological advancements are the factors anticipated to fuel the market growth during the forecast period.

Further key findings from the report suggest:

PSA test is increasingly being used to detect prostate cancer among men that showcase no typical symptoms of the disease thereby facilitating the segment growth

Biomarker tests include Prostate Health Index (PHI) and 4Kscore, predict the probability of a patient developing prostate cancer and are anticipated to garner significant market share over the forecast period

Technological advancements in the healthcare sector and increasing prevalence of the disease contributed significantly toward growth of the North America market

Some of the major players in the prostate cancer diagnostics market include MDxHealth; 3D Signatures; Genomic Health; Abbott; OPKO Health, Inc.; Siemens Healthineers; bioMerieux SA; and F. Hoffman La Roche Ltd

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market segmentation & scope
  • 1.2 Market definition
  • 1.3 Information procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources & Third Party Perspectives
    • 1.3.4 Primary Research
  • 1.4 Information analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market formulation & data visualization
  • 1.6 Data validation & publishing

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights

Chapter 3 Prostate Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Penetration And Growth Prospect Mapping
    • 3.2.1 User Perspective Analysis
      • 3.2.1.1 Consumer Behavior Analysis
  • 3.3 Regulatory Framework
    • 3.3.1 Reimbursement Framework
    • 3.3.2 Standards And Compliances
  • 3.4 Market Dynamics
    • 3.4.1 Market Driver Analysis
      • 3.4.1.1 Increasing Prevalence Of Prostate Cancer
      • 3.4.1.2 Increasing Government Initiatives
      • 3.4.1.3 Technological Advancements
    • 3.4.2 Market Restraint Analysis
      • 3.4.2.1 High Cost Of Diagnosis
    • 3.4.3 Market Opportunities Analysis
    • 3.4.4 Market Challenges Analysis
  • 3.5 Prostate Cancer Diagnostics Market Analysis Tools
    • 3.5.1 Industry Analysis - Porter's
      • 3.5.1.1 Supplier Power
      • 3.5.1.2 Buyer Power
      • 3.5.1.3 Substitution Threat
      • 3.5.1.4 Threat from new entrants
      • 3.5.1.5 Competitive Rivalry
    • 3.5.2 Pestel Analysis
      • 3.5.2.1 Political Landscape
      • 3.5.2.2 Environmental Landscape
      • 3.5.2.3 Social landscape
      • 3.5.2.4 Services landscape
      • 3.5.2.5 Legal Landscape
    • 3.5.3 Major Deals And Strategic Alliances Analysis
      • 3.5.3.1 Joint ventures
      • 3.5.3.2 Mergers and acquisitions
      • 3.5.3.3 Licensing and partnership
      • 3.5.3.4 Services collaborations
      • 3.5.3.5 Strategic Divestments

Chapter 4 Prostate Cancer Diagnostics Market - Competitive Analysis

  • 4.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 4.2 Company Categorization
    • 4.2.1 List Of Key Distributors And Channel Partners
    • 4.2.2 Key Company Market Share Analysis, 2019
  • 4.3 Public Companies
    • 4.3.1 Company Market Position Analysis
  • 4.4 Private Companies
    • 4.4.1 List Of Key Emerging Companies
    • 4.4.2 Regional Network Map
    • 4.4.3 Company Market Position Analysis

Chapter 5 Prostate Cancer Diagnostics Market: Test Type Estimates and Trend Analysis

  • 5.1 Definition & Scope
  • 5.2 Test Type Market Share Analysis, 2019 & 2027
  • 5.3 Segment Dashboard
  • 5.4 Global Prostate Cancer Diagnostics Market, by Test Type, 2016 to 2027
  • 5.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027
  • 5.6 Preliminary Tests
    • 5.6.1 Preliminary Tests Market, 2016 To 2027 (USD Million)
  • 5.7 Confirmatory Tests
    • 5.7.1 Confirmatory Tests Market, 2016 To 2027 (USD Million)
      • 5.7.1.1 Pca3 Test
      • 5.7.1.1.1 Pca3 Test Market Size & Forecasts, 2016 To 2027 (USD Million)
      • 5.7.1.2 Trans-Rectal Ultrasound
      • 5.7.1.2.1 Trans-Rectal Ultrasound Market Size & Forecasts, 2016 To 2027 (USD Million)
      • 5.7.1.3 Biopsy
      • 5.7.1.3.1 Biopsy Market Size & Forecasts, 2016 To 2027 (USD Million)

Chapter 6 Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 6.1 Regional Market Snapshot
  • 6.2 Market Share Analysis by Country, 2019
    • 6.2.1 North America
      • 6.2.1.1 U.S.
      • 6.2.1.2 Canada
    • 6.2.2 Europe
      • 6.2.2.1 U.K.
      • 6.2.2.2 Germany
      • 6.2.2.3 Spain
      • 6.2.2.4 France
      • 6.2.2.5 Italy
      • 6.2.2.6 Russia
    • 6.2.3 Latin America
      • 6.2.3.1 Brazil
      • 6.2.3.2 Mexico
      • 6.2.3.3 Argentina
    • 6.2.4 Asia Pacific
      • 6.2.4.1 Japan
      • 6.2.4.2 China
      • 6.2.4.3 India
      • 6.2.4.4 South Korea
      • 6.2.4.5 Australia
      • 6.2.4.6 Singapore
    • 6.2.5 Middle East & Africa
      • 6.2.5.1 South Africa
      • 6.2.5.2 Saudi Arabia
      • 6.2.5.3 Uae
  • 6.3 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
    • 6.3.1 North America
    • 6.3.2 Europe
    • 6.3.3 Latin America
    • 6.3.4 Asia Pacific
    • 6.3.5 Middle East & Africa
  • 6.4 Market Size & Forecasts, and Trend Analysis, 2016 to 2027
    • 6.4.1 North America
      • 6.4.1.1 Market Size, & Forecasts And Trend Analysis, 2016 To 2027 (USD Million)
      • 6.4.1.2 U.S.
      • 6.4.1.2.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.1.3 Canada
      • 6.4.1.3.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
    • 6.4.2 Europe
      • 6.4.2.1 Market Size, & Forecasts And Trend Analysis, 2016 To 2027 (USD Million)
      • 6.4.2.2 U.K.
      • 6.4.2.2.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.2.3 Germany
      • 6.4.2.3.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.2.4 France
      • 6.4.2.4.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.2.5 Italy
      • 6.4.2.5.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.2.6 Spain
      • 6.4.2.6.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.2.7 Russia
      • 6.4.2.7.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
    • 6.4.3 Asia Pacific
      • 6.4.3.1 Market Size, & Forecasts And Trend Analysis, 2016 To 2027 (USD Million)
      • 6.4.3.2 Japan
      • 6.4.3.2.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.3.3 China
      • 6.4.3.3.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.3.4 India
      • 6.4.3.4.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.3.5 South Korea
      • 6.4.3.5.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.3.6 Australia
      • 6.4.3.6.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.3.7 Singapore
      • 6.4.3.7.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
    • 6.4.4 Latin America
      • 6.4.4.1 Market Size, & Forecasts And Trend Analysis, 2016 To 2027 (USD Million)
      • 6.4.4.2 Brazil
      • 6.4.4.2.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.4.3 Mexico
      • 6.4.4.3.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.4.4 Argentina
      • 6.4.4.4.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
    • 6.4.5 Middle East & Africa
      • 6.4.5.1 Market Size, & Forecasts And Trend Analysis, 2016 To 2027 (USD Million)
      • 6.4.5.2 South Africa
      • 6.4.5.2.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million)
      • 6.4.5.3 Saudi Arabia
      • 6.4.5.3.1 Market Size & Forecasts and Trend Analysis, By Test Type, 2016 to 2027 (USD Million)
      • 6.4.5.4 UAE
      • 6.4.5.4.1 Market Size & Forecasts and Trend Analysis, By Test Type, 2016 to 2027 (USD Million)

Chapter 7 Company Profiles

  • 7.1 Company Profiles
    • 7.1.1 MDXHEALTH
      • 7.1.1.1 Company overview
      • 7.1.1.2 Financial Performance
      • 7.1.1.3 Product benchmarking
      • 7.1.1.4 Strategic initiatives
    • 7.1.2 3D SIGNATURES
      • 7.1.2.1 Company overview
      • 7.1.2.2 Financial Performance
      • 7.1.2.3 Product benchmarking
      • 7.1.2.4 Strategic initiatives
    • 7.1.3 GENOMIC HEALTH
      • 7.1.3.1 Company overview
      • 7.1.3.2 Financial Performance
      • 7.1.3.3 Product benchmarking
      • 7.1.3.4 Strategic initiatives
    • 7.1.4 ABBOTT
      • 7.1.4.1 Company overview
      • 7.1.4.2 Financial Performance
      • 7.1.4.3 Product benchmarking
      • 7.1.4.4 Strategic initiatives
    • 7.1.5 OPKO HEALTH, INC.
      • 7.1.5.1 Company overview
      • 7.1.5.2 Financial Performance
      • 7.1.5.3 Product benchmarking
      • 7.1.5.4 Strategic initiatives
    • 7.1.6 SIEMENS HEALTHCARE GMBH
      • 7.1.6.1 Company overview
      • 7.1.6.2 Financial Performance
      • 7.1.6.3 Product benchmarking
      • 7.1.6.4 Strategic initiatives
    • 7.1.7 DIASORIN S.P.A.
      • 7.1.7.1 Company overview
      • 7.1.7.2 Financial Performance
      • 7.1.7.3 Product benchmarking
      • 7.1.7.4 Strategic initiatives
    • 7.1.8 BIOMERIEUX SA
      • 7.1.8.1 Company overview
      • 7.1.8.2 Financial Performance
      • 7.1.8.3 Product benchmarking
      • 7.1.8.4 Strategic initiatives
    • 7.1.9 F. HOFFMAN LA ROCHE LTD.
      • 7.1.9.1 Company overview
      • 7.1.9.2 Financial Performance
      • 7.1.9.3 Product benchmarking
      • 7.1.9.4 Strategic initiatives
    • 7.1.10 BECKMAN COULTER, INC.
      • 7.1.10.1 Company overview
      • 7.1.10.2 Financial Performance
      • 7.1.10.3 Product benchmarking
      • 7.1.10.4 Strategic initiatives
    • 7.1.11 MYRIAD GENETIC, INC.
      • 7.1.11.1 Company overview
      • 7.1.11.2 Financial Performance
      • 7.1.11.3 Product benchmarking
      • 7.1.11.4 Strategic initiatives